Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3396260rdf:typepubmed:Citationlld:pubmed
pubmed-article:3396260lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C1708335lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C0015772lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:3396260lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:3396260pubmed:issue6lld:pubmed
pubmed-article:3396260pubmed:dateCreated1988-8-26lld:pubmed
pubmed-article:3396260pubmed:abstractTextThe pharmacokinetics and antihypertensive effects of felodipine, a new dihydropyridine calcium channel blocker, were studied in elderly hypertensive patients, 67 to 79 years of age and in young healthy subjects, 20 to 34 years of age following oral administration of 5 mg twice daily to steady-state. A single intravenous dose of 3H-felodipine (0.04mg) was given together with the oral dose on the study day. Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects. Systemic availability was about 15% in both groups. Plasma clearance (CL) was reduced from 56.1 L/h in the young to 25.4 L/h in the elderly. There was no effect of age on the volume of distribution at steady-state (Vss). Reduced hepatic blood flow and enzyme activity or increased gut wall metabolism are possible reasons for the altered pharmacokinetics in the elderly. Blood pressure was reduced in the elderly from 190/99 to 177/91 mm Hg 12 hours after 5mg felodipine during twice daily dosage. The effect on blood pressure correlated with plasma concentrations of felodipine.lld:pubmed
pubmed-article:3396260pubmed:languageenglld:pubmed
pubmed-article:3396260pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3396260pubmed:citationSubsetIMlld:pubmed
pubmed-article:3396260pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3396260pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3396260pubmed:statusMEDLINElld:pubmed
pubmed-article:3396260pubmed:monthJunlld:pubmed
pubmed-article:3396260pubmed:issn0312-5963lld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:RegårdhC GCGlld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:LundborgPPlld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:LandahlSSlld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:LarssonMMlld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:GabrielssonMMlld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:EdgarBBlld:pubmed
pubmed-article:3396260pubmed:authorpubmed-author:LernfeltBBlld:pubmed
pubmed-article:3396260pubmed:issnTypePrintlld:pubmed
pubmed-article:3396260pubmed:volume14lld:pubmed
pubmed-article:3396260pubmed:ownerNLMlld:pubmed
pubmed-article:3396260pubmed:authorsCompleteYlld:pubmed
pubmed-article:3396260pubmed:pagination374-83lld:pubmed
pubmed-article:3396260pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:meshHeadingpubmed-meshheading:3396260-...lld:pubmed
pubmed-article:3396260pubmed:year1988lld:pubmed
pubmed-article:3396260pubmed:articleTitlePharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.lld:pubmed
pubmed-article:3396260pubmed:affiliationDepartment of Long Term Care, Vasa Hospital, Göteborg.lld:pubmed
pubmed-article:3396260pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3396260pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3396260lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3396260lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3396260lld:pubmed